We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel Small Molecule POC Biosensor Technology to Revolutionize Early Disease Detection

By LabMedica International staff writers
Posted on 11 Mar 2024
Print article
Image: Conceptual representation of the research (Photo courtesy of POSTECH)
Image: Conceptual representation of the research (Photo courtesy of POSTECH)

Aptamers, biosensors made from nucleic acids that bind to specific proteins or small molecules, are increasingly employed in diagnosing various diseases. Their application in cancer detection is particularly promising due to the high cure rate possible with early cancer detection. However, aptamers face significant challenges, such as susceptibility to degradation or aggregation by nucleases and charged proteins found in biological samples like blood or saliva. This limitation has hampered their direct use in clinical samples without prior removal of these molecules. Now, a research team has addressed this issue by using a protein-based microcapsule.

Researchers from Pohang University of Science and Technology (POSTECH, Gyeongbuk, Korea) have devised an aptamer sensor system capable of rapid detection of target molecules directly from biological samples, thus eliminating the need for pretreatment processes. They have developed spherical microcapsules called proteinosomes, based on the self-assembly of protein-polymer amphiphiles. These microcapsules encase an aptasensor featuring a structure-switching aptamer that reacts with target molecules to emit a fluorescent signal instantly. The exterior of the microcapsule consists of a size-selective, semi-permeable membrane, designed to allow only small target molecules through while blocking larger, damaging proteins.

This innovative system maintains the aptasensor's optimal performance in untreated biofluids, thus enabling the efficient and quick detection of targets like estradiol, linked to reproductive organ cancers; dopamine, associated with Parkinson’s and Alzheimer’s diseases; and cocaine, which necessitates rapid detection. The capsules safeguard the aptasensors effectively against harmful proteins. For instance, aptasensors within these microcapsules remained unharmed for 18 hours in high concentration nuclease solutions, much more concentrated than typical serum levels. Moreover, by exploiting each capsule's capability to function as a distinct 'reaction vessel,' the team demonstrated the independent operation of multiple aptasensors in a single mixture. This allows for the simultaneous, real-time sensing of various target molecules and monitoring their concentration changes.

"By integrating sample separation and target detection, we have pioneered a novel small molecule point-of-care biosensor technology that is directly applicable to biological samples such as serum," said Professor Seung Soo Oh who led the research. "This platform has the potential to revolutionize medicine, spanning early disease detection and personalized treatment."

Related Links:
POSTECH

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.